Cationic liposomes for gene delivery

Purpose: Cationic liposome–DNA complexes (lipoplexes) are a potentially viable non-viral alternative to viral vectors for therapeutic gene delivery, but they suffer from limited delivery/gene expression efficiency, toxicity at higher concentrations, adverse interactions with serum and cell surfaces, and poor tissue access unless directly injected. Basic knowledge of lipoplex structure–activity relationships and intracellular delivery mechanisms remains scarce.

Hypothesis: As a review, there is no single experimental hypothesis. Central thesis: if the parameters governing lipoplex formation, physicochemical properties, cell interaction, intracellular trafficking, and in vivo behaviour are better understood and controlled, then cationic liposome–based gene delivery can be improved and made more clinically viable.

Aims: Review parameters governing lipoplex biological activity, from mode of formation to in vivo behaviour. - Emphasize mechanisms of interaction of cationic liposome–DNA complexes with cells and the barriers that must be surpassed for efficient gene expression. - Cover new trends in lipid-based gene delivery systems aimed at overcoming limitations. - Provide examples of cationic liposome applications in clinical gene therapy.

Delivery system: Platform: Cationic liposomes and lipoplexes. - Cationic lipids: DOTMA, DOTAP, DC-Chol, DMRIE, DOSPA, DOGS, and others. - Helper/colipids: DOPE, cholesterol, DOPC; PEG-phospholipid conjugates (PEG-PE). - Payloads: plasmid DNA, therapeutic genes, antisense oligonucleotides, oligonucleotides. - Condensing/targeting agents: polylysine, polyethylenimine (PEI), spermine, protamine, transferrin, folate, anti-CD3 antibody, cyclic RGD peptide, HVJ-liposome system, nuclear localisation signal (NLS) peptides. - Newer formulations: neutral or anionic liposomes encapsulating precondensed DNA; LPDII particles; artificial virus-like particles; water-soluble lipopolymers (WSLP).

Approach: Review/synthesis of in vitro, in vivo, and clinical studies. In vitro models include HeLa, Jurkat, macrophages, cardiac myocytes, and other cell types. In vivo models include mice, rabbit myocardium, and tumour models. Clinical contexts include cystic fibrosis, glioblastoma multiforme, metastatic melanoma, and breast/ovarian cancer. Not a systematic review.

Key methods: Biophysical characterisation of lipoplexes: size, zeta potential, colloidal stability, morphology. DNA protection assays: nuclease resistance, ethidium bromide accessibility. Cellular interaction/uptake: fluorescence microscopy, endocytosis pathway analysis. Transfection assays, cytokine response, biodistribution, and clinical trial endpoints.

Key results: Highly positively charged complexes had mean diameters of 100–450 nm; neutral complexes were heterogeneous at 350–1200 nm; large lipoplexes (>200 nm) were more effective in vivo than small complexes (50–100 nm). Time-dependent maturation produced homogeneous particles of 170–400 nm. - DOPE-containing liposomes generally gave higher in vitro transfection than DOPC; cholesterol-containing liposomes were more stable and active in vivo. - Serum inhibited transfection, but high cationic lipid/DNA charge ratios, prolonged complex formation, albumin, transferrin, or PEG-PE could enhance resistance/stability. - Clinical examples: CF trial with GL-67-DOPE-DMPE-PEG5000 showed significant chloride correction in all 8 patients, but influenza-like symptoms in 7/8. Repeated DC-Chol-DOPE administration was safe, with efficient gene transfer in 6/10 patients and no immune activation. IFN-β gene therapy for malignant glioma: transgene expression/antitumour activity in 4/5 patients; 2 had >50% tumour reduction and 2 had stable disease at 10 weeks. HSV-tk gene therapy for recurrent glioblastoma: >50% tumour volume reduction in 6/8 patients; treatment well tolerated in 2/8. Preclinical melanoma: cationic liposome–DNA gave a 5.5-fold reduction in mean tumour volume and tumour eradication in 18% of mice. - First clinical gene therapy success in SCID-X1 was later complicated by T-cell leukaemia in 2 children due to retroviral integration near LMO2.

Interpretation: Cationic liposomes are promising alternatives to viral vectors because of safety and versatility, and they have entered many clinical trials. However, efficacy remains far below viral vectors, especially when high and long-term transgene expression is required. Controlling formulation variables—size, charge, stability, cell interaction—may allow lipoplexes to be tailored for specific applications. Designing a non-viral vector that satisfies all conflicting delivery requirements remains difficult.

Limitations: This is a review, not a primary study. Cationic liposome efficacy is limited by serum interactions, toxicity, poor in vitro–in vivo correlation, and incomplete understanding of cellular uptake, endosomal escape, and nuclear entry. Clinical trials often show low gene transfer, and immune/inflammatory responses remain concerns. More complex formulations may compromise versatility, large-scale production, or repeated in vivo use.